News Search Results
Sep 29, 2026, 11:26 ET Velo Palmetto Joins Team In Training as Blood Cancer United Advances Goal of Giving Patients More Time
patients, families and caregivers.About Blood Cancer United®Blood Cancer United® (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research, and advocacy. Since their founding in 1949, the organization
More news about: BLOOD CANCER UNITED, INC.
Sep 29, 2026, 08:30 ET HUYABIO International Announces Pivotal Data for HBI-8000 in Advanced Melanoma Selected for Late-Breaking Presentation at ESMO Congress 2026
as monotherapy for the treatment of T-cell lymphoma in China (as Epidaza ®) and Japan (as HIYASTA®), and in combination with an aromatase inhibitor for breast cancer in China and Taiwan, and in combination with R-CHOP in diffuse large B-cell lymphoma in China.About the Phase 3 HBI-8000-303
More news about: HUYABIO International
Sep 28, 2026, 09:00 ET Kaluz Restaurant and Max's Grille Unite to Fight Blood Cancer
maxsgrille.com.About Blood Cancer UnitedBlood Cancer United® (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research, and advocacy. Since their founding in 1949, the organization
More news about: Arka Restaurant Group
Sep 28, 2026, 06:30 ET Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy
mainland China by Innovent Biologics.About Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)CLL/SLL is a form of slow-growing non-Hodgkin lymphoma that develops from white blood cells known as lymphocytes[6],[7]. CLL/SLL is one
More news about: Innovent Biologics
Sep 25, 2026, 17:11 ET FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
immune system problems. Olumiant may increase your risk of lymphoma and other cancers, including skin cancers. People taking a medicine in the class of medicines called JAK inhibitors have a higher risk of certain cancers, including lymphoma and lung cancer, especially if you are a current or past smoker.
More news about: Eli Lilly and Company
Sep 25, 2026, 07:00 ET Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
infectious disease specialists.In cases of refractory IEC-EC, consider additional workup to exclude alternative etiologies, including T-cell lymphoma of the GI tract, which has been reported in the post marketing setting.Secondary Malignancies: Patients treated with CARVYKTI® may
More news about: Johnson & Johnson
Sep 23, 2026, 08:00 ET Dechra Brings Laverdia® (verdinexor tablets), the First and Only FDA-Approved Oral Treatment for Dogs Diagnosed with Lymphoma
FDA-approved oral treatment for dogs diagnosed with lymphoma.1 Canine lymphoma is one of the most commonly diagnosed cancers in dogs, yet estimates suggest only about 20% of dogs with lymphoma receive chemotherapy. As a result, many families may benefit from additional treatment options
More news about: Dechra
Sep 22, 2026, 09:00 ET Deerfield Management and the Deerfield Foundation Announce the Fourth Annual AML Summit and Recipient of American Society of Hematology (ASH) Peter Steelman Scholar Award
Principal Investigator for an upcoming CLEC2A CAR-T cell trial for relapsed/refractory AML, building on research funded by NIH, the Leukemia & Lymphoma Society, and Hyundai Hope on Wheels, among others."Congratulations to Dr. Danielle Kirkey, whose work on the biology of KMT2A-rearranged AML
More news about: Deerfield Management Company, L.P.
Sep 22, 2026, 09:00 ET AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
extensive dryness, other serious manifestations may include profound fatigue, chronic pain, major organ involvement, neuropathy, and an increased risk of lymphoma. There are currently no FDA-approved medicines for Sjögren's disease."The results mark an important step forward for people living with Sjögren's
More news about: Amgen
Sep 22, 2026, 08:00 ET Cizzle Bio Champions Early Cancer Detection as Sponsor of Prevent Cancer Foundation's 32nd Annual Gala
prevention and early detection."Behnke, a dedicated patient advocate, has a personal connection to cancer. His daughter, Ella, was diagnosed with lymphoma at age 3, an experience that helped shape his longstanding commitment to patients and families. He also served on the 2026 Prevent Cancer Gala Committee
More news about: Cizzle Bio
Sep 22, 2026, 07:30 ET Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S.
More news about: Kazia Therapeutics Limited
Sep 22, 2026, 02:00 ET AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.MalignancyLymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active‑controlled study of
More news about: AbbVie
Sep 18, 2026, 11:00 ET NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMed
oncology and its growing CRO business in drug development. In veterinary medicine, ImpriMed has performed more than 27,000 tests for canine and feline lymphoma to guide treatment decisions. A retrospective study showed a threefold increase in survival time and a fourfold improvement in treatment response,
More news about: NAVER D2SF
Sep 16, 2026, 23:28 ET Sobi and Innate announce partnership is now effective following completion of closing conditions
cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL with first patient expected Q1 2027.Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma to support a planned
More news about: Swedish Orphan Biovitrum AB
Sep 16, 2026, 05:47 ET IASO Bio's CD20-Targeted In Vivo CAR-T Therapy IASO208 Receives FDA IND Clearance
in vivo, IASO208 enables the generation of anti-CD20 CAR-T cells directly within the patient's body.About Non-Hodgkin Lymphoma (NHL)Non-Hodgkin lymphoma (NHL) is a group of malignant tumors originating in the lymphatic system. According to GLOBOCAN estimates, approximately 563,000
More news about: IASO Bio
Sep 16, 2026, 04:52 ET LUNGevity Foundation Names Sam Rogers Chief Development Officer to Accelerate Investment in Lung Cancer Progress
driving philanthropic strategy and establishing pathways for sustainable growth.Earlier in his career, Rogers spent more than eight years at the Lymphoma Research Foundation, where his work spanned multiple fundraising channels, marketing, and patient communications. He earned both his Master of Science
More news about: LUNGevity Foundation
Sep 15, 2026, 16:30 ET Blood Cancer United Announces $7.5 Million Gift From Royalty Pharma to Expand Therapy Acceleration Program
www.royaltypharma.com.About Blood Cancer United®Blood Cancer United® (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research, and advocacy. Since their founding in 1949, the organization
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
Sep 15, 2026, 09:00 ET Brendan Valdes Joins Children's Miracle Network as Play Yellow Ambassador Ahead of Return to PGA Tour
Health Arnold Palmer Hospital for Children.Then, just before his first full professional season, Valdes was diagnosed with primary mediastinal lymphoma in January 2026. After undergoing treatment, he is now in remission and will return to professional golf after receiving an exemption into the Biltmore
More news about: Children's Miracle Network
Sep 14, 2026, 10:31 ET Bispecifics Market to Gain Momentum During the Forecast Period (2026-2036) with Expanding Pipeline and Increasing Therapeutic Adoption | DelveInsight
practices, addressable patient population, which includes top indications such as Acute Lymphocytic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Multiple Myeloma, Non-small-cell Lung Cancer (NSCLC), Small-cell Lung Cancer (SCLC), Biliary Tract Cancer (BTC), Rheumatoid Arthritis,
More news about: DelveInsight Business Research, LLP
Sep 10, 2026, 15:15 ET FDA Clears CU Anschutz Clinical Trial Using Engineered Immune Cells to Fight Colorectal Cancer
large numbers and returned to the patient.CAR T-cell therapies have produced remarkable results in some blood cancers, including leukemia and lymphoma. But developing CAR T-cell treatments for solid tumors such as colorectal cancer has proved much more difficult.One challenge is finding a target
More news about: University of Colorado Anschutz
Sep 09, 2026, 10:31 ET Waldenström Macroglobulinemia Market to Gain Momentum During the Forecast Period (2026-2036) Due to Launch of Novel Drug Classes Including BTK Degraders, Non-covalent BTKi, BCL-2 Inhibitors, and Targeted Radiotherapeutics | DelveInsight
Non-Hodgkin's Lymphoma MarketNon-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical
More news about: DelveInsight Business Research, LLP
Sep 09, 2026, 08:00 ET UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA®(certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)
cases were lymphoma, while the rest were other types of malignancies, including rare types associated with immunosuppression and malignancies not usually seen in this patient population.Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported
More news about: UCB
Sep 09, 2026, 07:30 ET Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S.
More news about: Kazia Therapeutics Limited
Sep 08, 2026, 10:34 ET PeproMene Bioは、再発・難治性B細胞リンパ腫において、CD19 CAR T細胞療法の事前治療が失敗した場合を含め、深く持続的な完全寛解が認められた画期的な第1相臨床試験の結果が『The Lancet』誌に掲載されたことを発表
Malignancies Instituteの所長であるStephen Forman医学博士は述べています。「City of Hopeは、患者の登録に加え、調整センターおよび製造拠点として、今後もこの臨床試験を支援し続けていきます。」2024年12月、Institute for Follicular Lymphoma Innovation (IFLI)は、再発または難治性の濾胞性リンパ腫患者を対象としたPMB-CT01の臨床開発を支援するため、最大1,100万ドルを拠出することを決定しています。「CD19を標的としたCAR T細胞療法を受けた後にリンパ腫が再発した患者にとって、新たな標的は新たな希望につながる可能性があります。IFLIは、PeproMene
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure
enrollment."In December 2024, the Institute for Follicular Lymphoma Innovation (IFLI) committed up to $11 million to support the clinical development of PMB-CT01 in patients with relapsed or refractory follicular lymphoma. "For patients whose lymphoma returns after CD19-directed CAR T-cell therapy, a new
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)